Background Air pollution has been proposed as a short-term trigger of multiple sclerosis (MS) relapses, but delayed effects ...

Background Approximately 1/3 of patients with epilepsy have drug-resistant epilepsy (DRE) and require surgical interventions. This meta-analysis aimed to review the effectiveness of MRI-guided laser ...

Three dissociations were observed in a case of alexia: a disturbance of reading, without comparable disturbance of oral expression, oral comprehension, writing, or spelling aloud; a disturbance of the ...

Background Limited data are available on the global rates of paediatric multiple sclerosis. Here, we report on the estimated worldwide prevalence of paediatric MS. Methods We included paediatric ...

3 Melbourne Brain Centre at Royal Melbourne Hospital, Melbourne, VIC, Australia Objectives To analyse John Cunningham virus (JCV) serology in natalizumab treated patients over time and assess whether ...

3 Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands 4 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands 5 Department of Clinical ...

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with the global epidemiological profile remaining incompletely understood. While previous systematic reviews existed ...

Objectives Recently, IgG autoantibodies against different paranodal proteins have been detected and this has led to important advances in the management of inflammatory neuropathies. In contrast, not ...

Background The high incidence of in-stent restenosis (ISR) associated with bare-metal stents (BMS) undermines the viability of endovascular treatment as a treatment option for patients with severe ...

Objective Intracranial atherosclerosis is a major cause of ischaemic stroke worldwide. A number of studies have shown the effects of statin treatment on coronary and carotid artery plaques, but there ...

Myasthenia gravis (MG) treatment’s landscape has dramatically changed with the approval of novel therapeutics that can provide rapid improvement, including in patients typically considered refractory.

Background We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) ...